MRCOG Part 2

This presentation is classic for HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), a severe variant of pre-eclampsia.

• Key features supporting HELLP syndrome:
  • Elevated liver enzymes (ALT 120, AST 115 – normal <40 U/L)
  • Thrombocytopenia (platelets 85,000 – normal >150,000/μL)
  • Elevated LDH (450 U/L – suggests hemolysis)
  • Hypertension and proteinuria (pre-eclamptic features)
  • Right upper quadrant/epigastric pain
• Why other options are less likely:
  • Option A: Acute fatty liver typically presents later (>35 weeks) with more severe coagulopathy and hypoglycemia
  • Option C: Severe pre-eclampsia alone wouldn’t explain the liver enzyme elevation and thrombocytopenia
  • Option D: Acute cholecystitis would show different pain pattern and wouldn’t cause thrombocytopenia
  • Option E: Hyperemesis gravidarum occurs in early pregnancy, not at 36 weeks

In a woman over 45 years with heavy menstrual bleeding and thickened endometrium, endometrial sampling is essential to exclude malignancy before considering treatment options.

• Key clinical features requiring investigation:
  • Age >45 years (increased risk of endometrial cancer)
  • Heavy menstrual bleeding with recent onset/change
  • Thickened endometrium (15mm – abnormal for reproductive age)
  • Need to exclude endometrial hyperplasia or carcinoma
• NICE guidance: Endometrial biopsy should be performed in women >45 years with heavy menstrual bleeding, particularly with thickened endometrium on ultrasound
• Why other options are premature:
  • Options A, C, D, E: All are potential treatments but inappropriate until malignancy is excluded
  • Histological diagnosis must precede treatment planning

Recurrent late decelerations indicate uteroplacental insufficiency and fetal hypoxia. Immediate intrauterine resuscitation should be attempted first.

• Late decelerations significance:
  • Indicate uteroplacental insufficiency
  • Gradual decrease in FHR beginning after contraction peak
  • Return to baseline after contraction ends
  • Associated with fetal hypoxia and acidosis
• Immediate intrauterine resuscitation measures:
  • Change maternal position (left lateral to improve venous return)
  • Administer high-flow oxygen
  • Increase IV fluids if hypotensive
  • Discontinue oxytocin if running
• Why other options are inappropriate initially:
  • Option A: Inappropriate to wait with pathological FHR pattern
  • Option B: Too precipitous – attempt resuscitation first
  • Option D: Cervix not fully dilated, head not engaged
  • Option E: May delay necessary intervention

This question tests the precise definitions related to infant mortality, which are crucial for audit, reporting, and counselling. The baby died on the 10th day of life, which falls into the late neonatal period.

Here is a breakdown of the key definitions according to the World Health Organization (WHO) and UK practice:

Clinical Pearl: The distinction between early and late neonatal death is important. Early deaths are often related to perinatal events (e.g., prematurity, birth asphyxia), while late deaths may also be due to infections or other complications acquired after birth.

This question assesses understanding of X-linked recessive inheritance.

• The father has the condition, so his genotype is X^cY (where ‘c’ is the recessive allele for colour blindness).
• The mother is unaffected and has no family history, so her genotype is X^CX^C.

We can use a Punnett square to determine the outcomes for their offspring:

• Daughters: All daughters inherit one X chromosome from their mother (X^C) and one from their father (X^c). Their genotype will be X^CX^c. Since the allele is recessive, they will be phenotypically normal but will be obligate carriers of the condition.
• Sons: All sons inherit one X chromosome from their mother (X^C) and the Y chromosome from their father. Their genotype will be X^CY. They will be phenotypically normal and unaffected.

Therefore, all of their daughters will be carriers, and all of their sons will be unaffected.

The investigation of choice to confirm a diagnosis of anaphylaxis is serum mast cell tryptase.

• Pathophysiology: During an anaphylactic reaction, mast cells degranulate, releasing large amounts of inflammatory mediators, including histamine and tryptase. While histamine has a very short half-life (minutes), tryptase levels remain elevated for several hours, making it a more reliable diagnostic marker.

• Why other options are incorrect:
  • Serum IgE level (B): Measures sensitisation to an allergen but does not confirm an acute anaphylactic event. It is useful in allergy testing later on.
  • Serum alkaline phosphatase (C): A marker of liver or bone function; it is irrelevant to anaphylaxis.
  • Plasma histamine (D): While released in anaphylaxis, its half-life is extremely short (1-2 minutes), making it very difficult to capture an elevated level in a clinical setting.
  • C-reactive protein (E): An acute phase reactant that rises in response to inflammation or infection over 12-24 hours, not acutely in anaphylaxis.

This question assesses knowledge of the Faculty of Sexual and Reproductive Healthcare (FSRH) guidance on missed pills and emergency contraception.

• Missed Pill Rule for Traditional POPs (e.g., Norethisterone): A pill is considered missed if it is taken more than 3 hours late. If one or more pills are missed, the woman is no longer protected against pregnancy. She needs to use extra precautions (e.g., condoms) for 2 days after she resumes taking her pills correctly.
• Need for EC: This woman missed two pills and had UPSI 48 hours ago. She is not protected and requires EC. Reassurance (Option D) is incorrect and dangerous. Taking extra POPs (Option E) is not a form of EC.

The choice of EC depends on effectiveness and timing:

Conclusion: The Cu-IUD is the most effective method and should be offered as the first-line option. If the patient declines an IUD or it is not available/contraindicated, UPA-EC would be the next best choice over LNG-EC given the 48-hour timeframe.

This question tests the management pathway for Premenstrual Syndrome (PMS) as outlined in NICE guideline NG23 (Menopause), which also covers PMS management.

The management of PMS is stepwise:

1. First-line (Mild symptoms): General lifestyle advice (diet, exercise, stress reduction).
2. Second-line (Moderate symptoms): A new-generation combined oral contraceptive pill (COCP) or a selective serotonin reuptake inhibitor (SSRI).
3. Third-line (Severe symptoms/Failure of 2nd line): If a standard COCP is ineffective, a trial of a COCP containing drospirenone is recommended.

• Why other options are incorrect:
  • COCP containing desogestrel (B): This is a standard COCP and would have likely been tried already as a second-line option. It lacks the specific anti-mineralocorticoid properties of drospirenone.
  • High-dose progestogen therapy (C): Not a recommended line of treatment and can sometimes worsen PMS symptoms.
  • GnRH analogues (D): This is a fourth-line option for very severe, refractory PMS, managed in a specialist setting. It induces a ‘medical menopause’ and requires add-back HRT.
  • Danazol (E): An androgenic steroid, not recommended for PMS due to its significant and often irreversible side effect profile.

This question relates to the British Association for Sexual Health and HIV (BASHH) guidelines for the management of individuals who have been sexually assaulted. The timing of testing is crucial to balance early detection with the need to wait for incubation periods to pass.

While some baseline tests may be taken at the initial presentation to check for pre-existing infections, the recommended follow-up screening is timed to maximise the yield for newly acquired infections.

Therefore, the most appropriate time for the initial comprehensive STI screening after the assault is at 2 weeks (14 days).

The clinical presentation is classic for Bacterial Vaginosis (BV). BV is not a classic infection but rather a dysbiosis, a shift in the vaginal flora from predominantly Lactobacillus species to a polymicrobial mix of anaerobic bacteria, with Gardnerella vaginalis being the most prominent.

The diagnosis is typically made using Amsel’s criteria (3 out of 4 required):

1. Thin, white/grey, homogenous discharge (as described).
2. Vaginal pH > 4.5 (patient’s pH is 5.5).
3. Positive ‘whiff’ test: a fishy odour (due to release of amines) when potassium hydroxide (KOH) is added to a sample of the discharge. The history of odour after intercourse is also classic (semen is alkaline).
4. Presence of ‘clue cells’ on wet mount microscopy (vaginal epithelial cells studded with coccobacilli).

Based on the description of a thin, grey-white discharge, a strong fishy odour, and an elevated pH, Bacterial Vaginosis is the most likely diagnosis, and Gardnerella vaginalis is the key organism involved.

In a pre-pubertal child, a persistent, foul-smelling, and often blood-stained or purulent (greenish/brownish) vaginal discharge is highly suggestive of a retained vaginal foreign body until proven otherwise.

• Clinical Presentation: Children may insert small objects like beads, crayons, or, most commonly, wads of toilet paper into the vagina. This leads to a local inflammatory reaction and secondary bacterial infection, causing the characteristic malodorous discharge.
• Management: The initial step is a careful external examination. If a foreign body is suspected, examination under anaesthesia (EUA) is often required for removal, especially in a young, anxious child. Vaginoscopy can aid visualisation. Sometimes, vaginal irrigation with saline in the clinic can dislodge the object.

The hallmark symptom of an ectopic ureter in a female is continuous urinary incontinence in the presence of a normal pattern of voiding. This is a classic presentation that must be recognised.

• Pathophysiology: An ectopic ureter is a congenital anomaly where the ureter does not insert into its normal position in the trigone of the bladder. In females, it can insert distal to the urethral sphincter, into the urethra, vagina, or uterus.
• Clinical Picture:
  • Because the ureter drains directly into the vagina (bypassing the bladder sphincter), there is a constant, uncontrollable trickle of urine.
  • The child also has a normal bladder and the other (correctly placed) ureter functions normally, so she will also have normal, periodic episodes of voiding.
  • This combination of continuous dribbling and normal voiding is pathognomonic.
  • It is often associated with a duplex renal system (a duplicated collecting system).

Investigation: The diagnosis is typically confirmed with imaging, such as an MR urogram or a renal ultrasound, to identify the duplex system and the ectopic ureter.

This question addresses the management of a dehisced (broken down) perineal wound, as per the RCOG Green-top Guideline No. 29 on Third- and Fourth-degree Perineal Tears, whose principles apply here.

• Wound Status: The key information is that the wound base is now clean and covered with healthy granulation tissue, and there are no signs of active infection. This indicates the wound is ready for definitive surgical management.
• Management Options:
  • Continued Conservative Management (B): While an option, healing by secondary intention can take a long time, result in a weak, cosmetically poor, and potentially painful or dysfunctional scar (e.g., causing dyspareunia). It is not the preferred option for a significant gaping wound.
  • Secondary Repair (A): This involves excising the wound edges and any unhealthy tissue (debridement) and then re-approximating the tissues with sutures. This is the treatment of choice for a clean, granulating, dehisced wound. It leads to faster healing and better functional and cosmetic outcomes compared to secondary intention. This should ideally be performed in theatre by an experienced clinician.

This patient presents with a complex picture of hyperemesis gravidarum complicated by a urinary tract infection (UTI) with signs of systemic illness (pyelonephritis). This requires inpatient management.

Breaking down the clinical picture:

• Hyperemesis Gravidarum: Severe vomiting, inability to tolerate fluids, and ketonuria are key features. This requires rehydration and antiemetics.
• Urinary Tract Infection (UTI): Dysuria, positive leucocytes and nitrites, and a significant E. coli growth confirm a UTI.
• Systemic Illness / Pyelonephritis: The presence of fever (38.2°C) and severe vomiting suggests the UTI is not just simple cystitis but has ascended to become pyelonephritis. Pyelonephritis in pregnancy is a serious condition that can lead to sepsis, preterm labour, and ARDS.

Option A is the only one that encompasses all the necessary immediate interventions for this sick pregnant patient.

This clinical scenario, particularly the combination of travel to an endemic area, anaemia, thrombocytopenia, splenomegaly, and FGR in pregnancy, is highly suggestive of Malaria.

• Key Pointers to Malaria:
  • Travel History: Rural Kenya is a high-risk, endemic area for malaria.
  • Haematological Changes: The triad of anaemia (due to haemolysis of red blood cells by the parasite) and thrombocytopenia is classic.
  • Splenomegaly: The spleen becomes enlarged as it works to clear infected red blood cells from the circulation.
  • Pregnancy Complications: Malaria in pregnancy is notorious for causing placental insufficiency, leading to fetal growth restriction (FGR), stillbirth, and preterm labour.
  • Symptoms: While fever is a classic symptom, it can be absent or intermittent. General malaise, headaches, and myalgia are common.

Management: Any pregnant woman with a fever or history of fever who has returned from a malaria-endemic area should be tested urgently with thick and thin blood films. Treatment should be started promptly based on the species identified (e.g., Plasmodium falciparum is most dangerous).

The clinical triad of symptoms described is classic for Measles (Rubeola virus).

The key features are often remembered by the “3 Cs”:

• Cough: A prominent, often harsh or ‘barking’ cough.
• Coryza: Symptoms of a head cold, runny nose.
• Conjunctivitis: Inflammation of the conjunctiva, leading to red, ‘bloodshot’ eyes, often with photophobia.

Other classic features include:

• Koplik’s spots: Small white spots (like grains of salt on a red background) on the buccal mucosa opposite the molars. They are pathognomonic but appear early and may be gone by the time the rash develops.
• Maculopapular Rash: A characteristic rash that begins on the face/behind the ears and spreads cephalocaudally (from head to toe). It is often blotchy and confluent.

Clinical Significance: Measles in pregnancy is a serious condition associated with an increased risk of miscarriage, stillbirth, preterm delivery, and maternal complications like pneumonia. The patient is highly infectious and requires isolation.

This is a classic presentation of MRKH syndrome, which is characterized by congenital aplasia (absence) of the uterus and the upper two-thirds of the vagina.

The management of a suspected tubo-ovarian abscess (TOA) in a post-menopausal woman is different from that in a pre-menopausal woman and requires a high index of suspicion for an underlying malignancy.

• The Concern: While TOAs are common in younger, sexually active women as a complication of Pelvic Inflammatory Disease (PID), they are rare in post-menopausal women. When they do occur, there is a significant association with an underlying gynaecological (e.g., ovarian, tubal, endometrial) or gastrointestinal malignancy. The malignancy can lead to necrosis, obstruction, and secondary infection, mimicking a primary abscess.
• The Correct Pathway: Because of this high risk of malignancy, any post-menopausal woman with a TOA or complex adnexal mass must be managed on a suspected cancer pathway.

• Why other options are incorrect:
  • Option A: Discussing in a general gynaecology MDT is not sufficient; this case requires specialist oncology input. The urgency is higher than a routine 4-week rescan and discussion.
  • Option B: While surgery is likely, the decision and timing should be made by the gynae-oncology team after MDT discussion, not as an automatic next step.
  • Option C: This is unsafe as it fails to investigate the high probability of an underlying malignancy.
  • Option E: A CA-125 test is useful but can be falsely elevated by infection/inflammation, making it unreliable in this acute setting. Management should not be based on this single marker; MDT discussion is paramount.

This question tests the knowledge of the crucial first aid steps following a sharps injury. While all the other actions are important parts of the subsequent management, the very first thing to do is manage the wound itself.

The Management Pathway (after first aid):

• Inform Senior / Report Incident: The doctor should immediately inform the senior surgeon or person in charge and report the incident locally (e.g., fill out an incident form).
• Risk Assessment: The doctor must seek urgent medical advice, usually from the Emergency Department or Occupational Health (OH). OH is the ideal place, but they are often not available 24/7, so the ED is the usual port of call out-of-hours.
• Source Patient Assessment: With informed consent, the source patient should be tested for HIV, Hepatitis B, and Hepatitis C. The patient is from a high-prevalence area for HIV (Caribbean), which increases the risk.
• PEP Decision: Based on the risk assessment (type of injury, viral load of source if known, etc.), a decision on starting Post-Exposure Prophylaxis (PEP) for HIV will be made. PEP should be started as soon as possible, ideally within 1 hour, and certainly within 72 hours.
• Hepatitis B Management: The doctor’s Hepatitis B immunity status will be checked. If they are a non-responder to the vaccine, Hepatitis B Immunoglobulin (HBIG) and a booster vaccine may be required.

While options A, B, and E are all correct and necessary next steps, they follow immediately after the first aid described in option C.

This question tests the management of endometrial hyperplasia without atypia based on the RCOG/BSGE Green-top Guideline (GTG) No. 67.

The management depends on whether there is atypia and on the woman’s menopausal status and desire for fertility.

Option A aligns with this guidance. After initial treatment (which should be offered), a 6-month follow-up biopsy is the correct next step. If this shows regression, a further biopsy in another 6 months would be performed before discharge.

This question addresses the opportunistic and patient-centred care for women with FGM, based on RCOG Green-top Guideline No. 53, Female Genital Mutilation and its Management.

• What is De-infibulation? It is a surgical procedure to open the scar tissue of Type 3 FGM, which involves the narrowing of the vaginal orifice with a covering seal.
• Why is it needed? It can alleviate long-term complications such as recurrent urinary and vaginal infections, dyspareunia, and difficulties with micturition and menstruation. It is also necessary for vaginal delivery.
• Timing of the Procedure:
  • Ideally, de-infibulation should be discussed and offered antenatally, to be performed in the second trimester.
  • If a woman presents in labour, it can be done during the first or second stage.
  • Crucially, if a woman with Type 3 FGM has a caesarean section, she should still be offered de-infibulation. The postnatal period, while she is still an inpatient, is an excellent opportunity to perform the procedure.

This question addresses the management of atypical endometrial hyperplasia (AEH) in a woman who wishes to preserve fertility, based on RCOG/BSGE GTG No. 67.

• Significance of Atypia: AEH is a precancerous condition. There is a high risk (up to 40%) of co-existent, underlying well-differentiated endometrial cancer. For women who have completed their family, the standard treatment is total hysterectomy (Option A).
• Fertility-Sparing Management: For a select group of women who wish to preserve fertility, a conservative approach can be considered after thorough counselling and investigation (including an MRI to exclude myometrial invasion).

Therefore, the correct pathway is to start treatment with an LNG-IUS and schedule the first follow-up biopsy in 3 months. Option C (6 months) is the correct interval for non-atypical hyperplasia but is not frequent enough for AEH.

This question tests the complex legal and safeguarding duties related to FGM in the UK. There are two key duties that apply here: the mandatory reporting duty to the police and the duty to safeguard children.

Conclusion: The professional has a dual responsibility: the legal duty to report the FGM in the 16-year-old mother to the police, and a professional safeguarding duty to refer to social services. Option E is the only one that captures both essential actions.

This question requires a systematic approach to diagnosing post-operative pyrexia. The timing of the fever is a key clue.

Common Causes of Post-operative Pyrexia (The “5 Ws”):

• Wind (Day 1-2): Chest infection, atelectasis (lung collapse).
• Water (Day 3-5): Urinary tract infection (UTI), especially if catheterised.
• Wound (Day 5-7): Surgical site infection (wound or deep).
• Walking (Day 5+): Deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Wonder drugs (Anytime): Drug-induced fever.

In this case:

• The fever starts on Day 5, which is a typical time for a deep-seated infection to manifest.
• A ‘swinging’ pyrexia (large fluctuations between high and normal/low temperatures) is highly suggestive of an abscess formation.
• Other common causes have been reasonably excluded by the clinical findings:
  • Pneumonia (C) is less likely as her chest is clear.
  • UTI (B) is less likely with a negative urine dipstick.
  • A superficial wound infection (D) is less likely as the wound is clean and dry and the abdominal exam is unremarkable.
  • DVT (E) can cause a low-grade fever but a swinging pyrexia is not typical.

This question tests the UK’s national antenatal screening programme for sickle cell disease and thalassaemia, as outlined by NICE and the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.

The programme aims to identify carrier couples (at-risk couples) so they can be offered prenatal diagnosis for the fetus.

This woman’s family history and South Indian ethnicity place her at higher risk, making screening essential. The correct initial laboratory test is the combination of an FBC and haemoglobin electrophoresis/HPLC.

• Option A: FBC is part of the test, but it’s insufficient on its own. Blood group is a separate routine test.
• Option C: Ferritin is tested to investigate microcytic anaemia to differentiate it from thalassaemia trait, but it is not the primary screening test for haemoglobinopathy.
• Option D: Specific DNA testing is a second-line investigation, used if the initial screening is inconclusive or for prenatal diagnosis.
• Option E: A sickle cell test is part of the screening but is not sufficient, as it would miss thalassaemia. Haemoglobin electrophoresis covers both.

This question requires a risk assessment for venous thromboembolism (VTE) in the postnatal period, based on RCOG Green-top Guideline No. 37a.

The decision to give thromboprophylaxis and for how long is based on a scoring system of pre-existing and transient risk factors.

Since this patient has a risk score of 5, she requires extended thromboprophylaxis with prophylactic dose LMWH for 6 weeks.

• Option A (10 days) is insufficient for her high-risk profile.
• Option C (Therapeutic LMWH) is incorrect. This dose is used for the treatment of an acute VTE, not for prophylaxis.

This question addresses the critical management of maternal cardiac arrest, specifically the role of the perimortem caesarean section (PMCS), also known as resuscitative hysterotomy.

In a pregnant woman beyond 20 weeks’ gestation, the gravid uterus causes significant aortocaval compression, which severely impedes venous return to the heart. This makes standard CPR much less effective.

The Primary Goal of PMCS is Maternal, Not Fetal:

• The primary purpose of the PMCS is to save the mother’s life.
• By emptying the uterus, aortocaval compression is relieved, which can dramatically improve venous return, cardiac output, and the effectiveness of CPR, potentially leading to ROSC.
• Saving the baby is a secondary, albeit important, benefit. The decision to perform PMCS should not be delayed by checking for a fetal heartbeat (Option C).

Why other options are incorrect:

• Option A: It is never appropriate to call off CPR at 4 minutes in this scenario; PMCS is the next life-saving step.
• Option C: Wastes time and the primary goal is maternal resuscitation.
• Option D: Waiting 30 minutes is far too long and removes any chance of successful maternal or fetal resuscitation.
• Option E: While these are components of ALS, they do not address the underlying mechanical problem of aortocaval compression. The PMCS must be done concurrently with ongoing high-quality CPR.

This question tests the specific definitions of maternal death used by the UK’s confidential enquiry, Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries (MBRRACE-UK). The classification of suicide has changed in recent years.

Previously, suicide was often classified as an indirect death. However, reflecting a greater understanding of perinatal mental health, MBRRACE-UK now classifies death from suicide in pregnancy or the postnatal period as a Direct Maternal Death.

The rationale for classifying suicide as a direct death is that pregnancy can be a significant trigger or exacerbating factor for severe mental illness, and therefore the death is a direct consequence of the “pregnant state”. This patient’s death from suicide, linked to her depression during pregnancy, is therefore classified as a direct maternal death.

This presentation is a classic example of late-onset (or non-classical) CAH, which can mimic PCOS. The key diagnostic clue is the elevated 17-hydroxyprogesterone (17-OHP) level.

• Pathophysiology: Late-onset CAH is most commonly due to a partial deficiency of the enzyme 21-hydroxylase. This deficiency leads to a block in the adrenal steroid synthesis pathway. Precursors like 17-OHP cannot be converted to cortisol, so they accumulate and are shunted down the androgen synthesis pathway, leading to hyperandrogenism.
• Clinical Features: It presents after puberty with signs of androgen excess: hirsutism, acne, and menstrual irregularity.

• Why other options are incorrect:
  • PCOS (A): Would not typically cause such a high 17-OHP level. It is a diagnosis of exclusion after ruling out conditions like CAH.
  • Androgen-secreting tumour (C): Usually has a more rapid onset of severe virilisation (e.g., clitoromegaly, voice deepening) and very high testosterone or DHEAS levels.
  • Cushing’s syndrome (D): Presents with features of cortisol excess (e.g., central obesity, striae, moon facies) and would be diagnosed with dexamethasone suppression tests or 24-hour urinary free cortisol.
  • Early-onset CAH (E): This is the classical, severe form presenting in infancy with ambiguous genitalia in females and salt-wasting crises.

The key to this diagnosis is the combination of rapid-onset virilisation in a post-menopausal woman and the specific biochemical marker that is elevated.

• Clinical Picture: The rapid onset of severe hyperandrogenic symptoms (virilisation: voice deepening, clitoromegaly) in a post-menopausal woman is highly suspicious for an androgen-secreting tumour.
• Biochemical Clue: The source of the tumour can often be pinpointed by the specific androgen that is most elevated.
  • Dehydroepiandrosterone sulfate (DHEAS) is produced almost exclusively by the adrenal glands. A markedly elevated DHEAS level points strongly to an adrenal source.
  • Testosterone is produced by both the ovaries and the adrenal glands (and peripheral conversion). A tumour primarily secreting testosterone would point towards an ovarian source.

Next Step: The next investigation for this patient would be imaging of the adrenal glands, typically with a CT or MRI scan, to locate the tumour.

• Why other options are incorrect:
  • Ovarian hyperthecosis (B) and Arrhenoblastoma (D) are ovarian sources and would cause a primary elevation in testosterone, not DHEAS.
  • Late-onset CAH (C) presents more gradually and is characterised by elevated 17-OHP.
  • Exogenous androgen use (E) is a possibility but a tumour must be excluded first in this context.

This question combines two key principles from the NICE guideline [NG137] on Twin and Triplet Pregnancy: the timing of birth for MCDA twins and the mode of birth when the second twin is non-cephalic.

Conclusion: Given the combination of being in the optimal delivery window for MCDA twins (36+0 to 37+0) and the breech presentation of the second twin, the safest and most appropriate recommendation is a planned caesarean section. Option C aligns perfectly with this. Induction of labour (Option B) is less ideal due to the breech second twin. ECV on a second twin (Option E) is not standard practice.

This question tests the understanding of fundamental clinical trial terminology. Let’s break down the components described in the vignette.

Combining these elements, the study is a double-blind, placebo-controlled, randomised trial, which is considered the gold standard for evaluating the efficacy of a new intervention.

• Why other options are incorrect:
  • Single-blind (B): Incorrect because both parties are blinded.
  • Meta-analysis (C): This is a statistical method for combining the results of multiple independent studies, not a design for a single trial.
  • Case-control study (D): This is an observational study that looks backwards in time, comparing people with a condition (cases) to those without (controls) to find risk factors.
  • Open-label trial (E): The opposite of a blind trial, where both participants and investigators know what treatment is being given.

This question tests a fundamental principle of medical education and assessment: the distinction between formative and summative assessments.

The Core Principle:

The nature of an assessment (formative or summative) must be agreed upon beforehand. Changing a formative assessment to a summative one retrospectively is fundamentally unfair and undermines the entire purpose of the assessment framework.

• The trainee entered the assessment with the low-stakes mindset of a formative exercise. Had she known it was summative, the pressure and her approach might have been different.
• Allowing a “good” formative assessment to become summative would create a system where trainees only put forward their best performances for judgement, which is not a true reflection of their overall competence.
• It compromises the integrity and validity of the assessment process.

The correct and professional response is to praise the trainee for her excellent performance, provide constructive feedback, and explain clearly and supportively why the assessment cannot be changed. You should encourage her to arrange a summative OSAT when she feels ready, confident that she will perform well.

This scenario deals with a potential issue of professionalism and probity. The General Medical Council (GMC) guidance on ‘Good Medical Practice’ states that doctors must be honest and trustworthy. The management of such concerns should be supportive and proportionate in the first instance.

Why other options are inappropriate initially:

• Options B and C (Warnings): These are punitive and escalatory. A warning should not be the first step without first understanding the context and giving the trainee a chance to explain and learn.
• Option D (Report to GMC): This is a significant escalation reserved for serious, persistent, or deliberate acts of dishonesty where local resolution has failed or is inappropriate. It is not the initial step for this kind of issue.
• Option E (Discuss with College Tutor first): While you may need to involve the College Tutor later, your primary responsibility as the educational supervisor is to address the issue directly and supportively with your trainee first. Bypassing the trainee can undermine trust.

The key is to handle the situation constructively, focusing on learning and professional development, unless the dishonesty is found to be deliberate and malicious, at which point escalation would be necessary.

This question asks for the definitive management of a recurrent Bartholin’s abscess. While several options exist, some are better than others for preventing recurrence.

Conclusion:

Given that this patient has a recurrent abscess that failed simple I&D previously, the goal is to prevent it from happening again. Marsupialisation is the standard surgical procedure for this purpose. Insertion of a Word catheter (Option E) is also an excellent and less invasive alternative, but marsupialisation is the classic surgical answer and is highly effective. Repeat I&D (Option D) is likely to fail again. Excision (Option C) is overly aggressive for a first recurrence.

This question highlights a specific therapeutic option in the management of PMS, focusing on the pharmacological properties of different progestogens. The key to the answer lies in the term ‘anti-mineralocorticoid’.

According to NICE guideline NG23 and RCOG guidance, the management of PMS is stepwise. When first-line options like lifestyle changes and SSRIs fail, hormonal manipulation is considered.

The other progestogens listed (Desogestrel, Levonorgestrel, Norethisterone, Medroxyprogesterone acetate) do not possess this significant anti-mineralocorticoid effect; some may even have mild mineralocorticoid activity, potentially worsening fluid retention.

The decision for adjuvant therapy in early-stage endometrial cancer is based on risk stratification to predict the likelihood of recurrence. This patient’s cancer falls into the intermediate-risk category.

Risk Stratification (ESGO/ESTRO/ESP Guidelines):

• FIGO Stage IB: Tumour invades ≥50% of the myometrium.
• Grade 2: Moderately differentiated.
• LVSI: Absent.

This combination (Stage IB, Grade 1-2) places her in the intermediate-risk group.

Rationale for Brachytherapy:

• For intermediate-risk patients, the most common site of recurrence is the vaginal vault.
• Vaginal vault brachytherapy is highly effective at reducing the risk of local recurrence at the vault.
• Large trials (e.g., PORTEC-2) have shown that for this risk group, brachytherapy provides similar control of vaginal recurrence as external beam radiotherapy (EBRT) but with significantly fewer long-term side effects (e.g., bowel and bladder toxicity).

Therefore, for this patient with Stage IB Grade 2 disease, adjuvant vaginal vault brachytherapy is the standard of care.

The combination of signs and symptoms in this post-operative patient points strongly to a subphrenic abscess (a collection of pus below the diaphragm).

Let’s analyse the key clinical features:

• Setting: Post-abdominal surgery (caesarean section), particularly for an infective indication (chorioamnionitis), which increases the risk of intra-abdominal collections.
• Timing: Day 7 is a classic time for a deep-seated abscess to present.
• Shoulder Tip Pain: This is the most specific clue. The phrenic nerve (C3, C4, C5) supplies the diaphragm. Irritation of the diaphragmatic peritoneum by an underlying abscess causes pain that is referred to the dermatomes of C3-C5, which is the skin over the shoulder tip.
• Right Upper Quadrant (RUQ) Pain: This is the location of the abscess.
• Respiratory Signs: The “stony dullness” at the lung base is not from the lung itself (pneumonia) but from the abscess pushing the diaphragm upwards and causing a reactive pleural effusion and/or basal lung collapse (atelectasis). The chest may be clear on auscultation initially.

Next Step: Diagnosis is confirmed with a CT scan of the abdomen and pelvis. Management involves IV antibiotics and drainage of the abscess.

The management of Atypical Endometrial Hyperplasia (AEH) requires careful and intensive follow-up due to its nature as a premalignant condition with a high risk of co-existing or progressing to endometrial cancer.

According to the RCOG/BSGE Green-top Guideline No. 67, while total hysterectomy is the standard treatment, fertility-sparing conservative management can be offered to carefully selected and counselled women. This management requires a strict surveillance protocol.

This contrasts with hyperplasia without atypia, where the risk is much lower, and the recommended follow-up interval is 6 months.

This patient is presenting with the classic “pentad” of symptoms and signs for Thrombotic Thrombocytopenic Purpura (TTP), a life-threatening medical emergency.

Management: TTP is a medical emergency requiring urgent plasma exchange (PEX) and immunosuppression (e.g., steroids).

This question focuses on the long-term side effects of specific chemotherapy agents and their implications for pregnancy.

Doxorubicin is an anthracycline antibiotic, a class of chemotherapy drugs widely used for various cancers. The most significant and well-known long-term toxicity of anthracyclines is dose-dependent cardiotoxicity.

Therefore, it is absolutely essential to assess her baseline cardiac function before she conceives. An echocardiogram is the investigation of choice to evaluate left ventricular ejection fraction (LVEF) and overall cardiac structure and function.

Why other options are less critical as the primary investigation:

• Chest X-ray (B) and Pulmonary function tests (C): These would be important if she had received bleomycin (known for pulmonary fibrosis) or chest radiotherapy, but doxorubicin’s primary target is the heart.
• AMH level (D): This assesses ovarian reserve, which is certainly important for her fertility potential after chemotherapy. However, maternal safety takes precedence. Assessing her cardiac risk is the most critical step to ensure she can safely carry a pregnancy.
• Full blood count (E): This is a routine test but does not address the specific long-term toxicity of doxorubicin.

The management of labour in women with significant cardiac disease is a key topic, guided by the RCOG Green-top Guideline on Cardiac Disease in Pregnancy.

The Problem with the Second Stage:

The second stage of labour, particularly active pushing (the Valsalva manoeuvre), places immense strain on the cardiovascular system. It causes large swings in intra-thoracic pressure, venous return, and cardiac output. In a patient with a fixed cardiac output lesion like severe aortic stenosis, this can lead to haemodynamic collapse, arrhythmias, or even death.

Why other options are incorrect:

• Options A and D (Passive descent/Active pushing): Both prolong the second stage and/or involve maternal pushing, which is precisely what needs to be avoided.
• Option C (Immediate CS): This is not indicated. The patient is fully dilated with the head low in the pelvis, making an instrumental delivery the most appropriate and least morbid option, provided it is done in a safe environment. A CS at this stage would be difficult and carry its own risks.
• Option E (Instrumental in the room): This is unsafe. For a high-risk cardiac patient, the delivery must be conducted in theatre with full anaesthetic, obstetric, and cardiology support immediately available.

This question requires an understanding of the pathophysiology of MRKH syndrome and the reproductive technologies available.

Recap of MRKH Syndrome:

• It is a congenital disorder in 46,XX females characterised by Müllerian duct aplasia, leading to an absent uterus and upper vagina.
• Crucially, the ovaries are present and function normally. These women produce their own eggs (oocytes) and ovulate.

The goal is to have a child that is “genetically their own”. This means the child must come from the woman’s egg and her partner’s sperm.

Why other options are incorrect:

• IVF with donor eggs (B): This would not result in a child that is genetically the woman’s own.
• Uterine transplant (C): While this is an emerging and remarkable technology, it is still highly experimental, carries significant surgical and immunological risks, and is not a standard or widely available option.
• Adoption (D): This is a valid way to build a family but does not result in a genetically related child.
• Traditional surrogacy (E): This is where the surrogate’s own egg is fertilised (usually by IUI) with the male partner’s sperm. The child would be genetically related to the father and the surrogate, not the woman with MRKH.

Pregnancies conceived via oocyte (egg) donation are known to be associated with a specific profile of increased obstetric risks. The most significant and well-documented of these is a markedly increased risk of hypertensive disorders.

This increased risk means these pregnancies require closer surveillance, including more frequent blood pressure monitoring and assessment for proteinuria. Low-dose aspirin from 12 weeks’ gestation should be strongly recommended.

While other risks like placenta praevia and PPH are increased in IVF pregnancies in general, the most pronounced and specific risk associated with oocyte donation itself is the development of hypertensive disorders.

This question addresses a key risk associated with Hormone Replacement Therapy (HRT), as outlined in NICE guideline NG23 (Menopause).

It is crucial to distinguish between the risks of oral versus transdermal HRT.

Therefore, the most accurate description for oral HRT is that it doubles the background risk. A ten-fold increase (Option C) is a significant overestimation.

This question tests knowledge of the pharmacokinetics of local anaesthetics, which is crucial for understanding both their efficacy and the timing of potential systemic toxicity.

The rate of absorption of a local anaesthetic into the bloodstream, and thus the time to peak plasma concentration, depends heavily on the vascularity of the injection site.

Therefore, the 20-30 minute timeframe is the correct answer for the peak plasma level after perineal infiltration.

This is a complex counselling case that requires knowledge of the RCOG Green-top Guideline No. 45 (Birth after Previous Caesarean Birth).

While a trial of labour after one CS (VBAC) is a common and safe option for many, the risk of uterine rupture increases with the number of previous caesarean sections. The specific indication for the previous CS is also critical.

Conclusion for this Patient:

This woman has two major risk factors against a trial of labour:

1. She has had two previous caesarean sections.
2. One of these was for placenta praevia, which raises specific concerns about the integrity of that scar.

Given this combination of high-risk factors, a trial of labour (VBAC) would carry a substantial risk of uterine rupture. The safest and most appropriate recommendation is to advise her to have a planned elective repeat caesarean section (ERCS) at around 39 weeks’ gestation. While her autonomy must be respected, she should be strongly counselled that VBAC is not the recommended or safest option in her specific circumstances.

This patient has severe, refractory PMDD, having failed multiple lines of evidence-based treatment. The management pathway, as per RCOG and NICE guidance, escalates to suppressing the underlying hormonal cycle.

Conclusion: For this patient who has failed standard treatments, a trial of a GnRH agonist with add-back HRT is the correct next step. It is both diagnostic (proves hormone dependency) and therapeutic, and is the necessary precursor to considering definitive surgery.

Tranexamic acid is a non-hormonal medical treatment for heavy menstrual bleeding (HMB). Its mechanism of action is based on inhibiting the breakdown of blood clots.

It does not affect the coagulation cascade itself (A, C), platelet function (D), or the endometrium (E). It purely acts to stop clots from being broken down too quickly.

This is a complex scenario that requires careful application of the NICE guideline [NG25] on Preterm Labour and Birth and RCOG guidance.

Let’s break down the patient’s risk factors and current findings:

• History: One previous second-trimester loss. This is a major risk factor for recurrence. The fact a cerclage was placed in that pregnancy suggests cervical weakness was suspected.
• Current Finding: A short cervix (19 mm) detected on scan at 20 weeks. A cervix <25 mm before 24 weeks is considered short and a significant predictor of preterm birth.

The management strategy depends on the combination of history and ultrasound findings.

Conclusion: The combination of a history of second-trimester loss and the current finding of a short cervix (19 mm) is a clear indication for an ultrasound-indicated cerclage. While vaginal progesterone is also an option, the cerclage is strongly indicated by the combination of risk factors. Continuing with serial scans (Option C) is incorrect because a significant finding has already been made and action is required.

The clinical presentation of a single, painless, indurated ulcer (a chancre) is classic for primary syphilis. However, the serological tests are negative. This discrepancy can be explained by the natural history of the infection and the immune response.

Clinical Management:

In a patient with a clinically classic chancre, treatment should not be withheld because of negative initial serology. The correct approach is:

1. Treat based on clinical suspicion with a single dose of intramuscular Benzathine Penicillin G.
2. Repeat the syphilis serology in 2-4 weeks, by which time it is expected to have become positive.

Why other options are incorrect:

• Prozone phenomenon (A): This is a rare cause of a false-negative VDRL/RPR test that occurs in secondary syphilis, when antibody levels are so high that they interfere with the lattice formation needed for a positive result. It does not affect treponemal tests like TPPA/EIA.
• Biological false negative (B): This term is not standard. The opposite, a biological false positive, is common with non-treponemal tests.
• The ulcer is not caused by syphilis (D): While possible, the description is so classic for a chancre that syphilis remains the top differential and must be treated presumptively.

This question tests the interpretation of syphilis serology, particularly discordant results between non-treponemal and treponemal tests.

Interpreting the Results:

• RPR Positive: Suggests possible syphilis infection OR another condition.
• TPPA Negative: This specific test rules out syphilis (past or present).

When the non-specific test (RPR) is positive, but the specific confirmatory test (TPPA) is negative, the result is a Biological False Positive (BFP). This means the RPR test has reacted to cardiolipin antibodies produced for a reason other than syphilis.

This patient’s history of rheumatoid arthritis is a classic cause of a BFP. The negative TPPA confirms she does not have syphilis.

This constellation of symptoms is classic for Behçet’s disease, a multi-system inflammatory disorder (vasculitis) of unknown aetiology. It is more common in people with origins along the old “Silk Road,” including the Mediterranean, Middle East, and Far East.

The diagnosis is clinical, based on the International Study Group criteria.

This patient meets the criteria:

1. Recurrent oral ulcers (present)
2. Recurrent genital ulcers (present)
3. Skin lesions (pustular lesions present)
4. She also has arthritis, which is another common feature of the disease.

Why other options are less likely:

• Erosive Lichen Planus (B): Can cause painful oral and genital ulcers, but systemic features like arthritis and pustular skin lesions are not typical. It often has characteristic lacy white (Wickham’s) striae.
• SLE (C): Can cause oral ulcers and arthritis, but genital ulcers are less common, and the typical skin lesion is a malar (butterfly) rash.
• Crohn’s disease (D): Can cause oral ulcers, arthritis, and skin lesions (erythema nodosum), but genital ulcers are less common, and it is primarily an inflammatory bowel disease.
• Herpes Simplex (E): Causes recurrent vesicular outbreaks, not aphthous ulcers, and does not cause this pattern of systemic inflammation.

The clinical description is classic for Chancroid, a sexually transmitted infection caused by the bacterium Haemophilus ducreyi. It is rare in the UK but endemic in parts of Africa, Asia, and the Caribbean.

This patient’s combination of a painful ulcer with a purulent base and painful, suppurative lymph nodes is pathognomonic for Chancroid.

This is a high-risk obstetric emergency. The management is guided by BHIVA (British HIV Association) guidelines for the management of HIV in pregnancy.

The risk of mother-to-child transmission (MTCT) of HIV is directly related to the maternal viral load at the time of delivery. If the viral load is >50 copies/mL (or is unknown), specific interventions are required.

Why other options are incorrect:

• Vaginal delivery (B): This is only recommended if the maternal viral load is known to be <50 copies/mL. It is unsafe in this situation.
• Artificial rupture of membranes (C): This would be dangerous. Prolonged rupture of membranes (>4 hours) significantly increases the risk of MTCT. Membranes should be kept intact for as long as possible.
• Oral nevirapine (D): While used in some resource-poor settings, the UK guideline prioritises IV zidovudine and CS.
• HIV spot test (E): The patient has disclosed she is positive. While bloods should be sent for confirmation and viral load, waiting for a result is not necessary or appropriate. Management to reduce MTCT must begin immediately based on her disclosure.

The combination of IV zidovudine and caesarean section offers the maximal reduction in transmission risk when the viral load is unknown.

The clinical presentation is highly suggestive of Lichen Planus, a chronic inflammatory condition that can affect the skin, hair, nails, and mucous membranes.

Why MDT Referral is the Best Step:

Lichen planus is a complex, challenging condition to manage. It has a small but significant risk of malignant transformation to squamous cell carcinoma in long-standing erosive disease.

• Diagnostic Complexity: It can be difficult to differentiate from other vulval dermatoses. While a biopsy (Option D) is essential for diagnosis, it is best performed by a specialist who knows the optimal site to biopsy.
• Therapeutic Complexity: Management requires specialist expertise, often involving super-potent topical steroids (e.g., clobetasol propionate), calcineurin inhibitors (e.g., tacrolimus), and sometimes systemic immunosuppressants.
• Multidisciplinary Approach: Given the involvement of the vulva, mouth, and scalp, a coordinated approach involving a gynaecologist, dermatologist, and sometimes an oral medicine specialist is ideal. This is best achieved in a dedicated vulval MDT clinic.

Therefore, referring her to this specialist service is the safest and most appropriate next step. They will coordinate the biopsy, confirm the diagnosis, and initiate the correct, often complex, treatment plan.

In a post-menopausal woman, any new, persistent, or suspicious vulval lesion that does not respond to treatment must be considered malignant until proven otherwise. The primary concern is vulval intraepithelial neoplasia (VIN) or invasive squamous cell carcinoma (SCC).

The Essential Next Step: Biopsy

A histological diagnosis is mandatory. The standard procedure to obtain a tissue sample from a vulval lesion is a punch biopsy.

• Punch Biopsy: This is a simple, quick procedure that can be performed in an outpatient clinic under local anaesthesia. A small, circular blade (typically 3-5 mm) is used to obtain a full-thickness sample of the skin for histopathological analysis. It provides an accurate diagnosis with minimal morbidity.
• Excisional Biopsy (A): This involves removing the entire lesion. While it can be both diagnostic and therapeutic, it is generally reserved for smaller lesions or when a punch biopsy has already confirmed a diagnosis that requires excision. For initial diagnosis of a suspicious 1 cm lesion, a punch biopsy is the standard first step.

Why other options are incorrect:

• Further steroids (C): Inappropriate and potentially dangerous as it would delay the diagnosis of a potential cancer.
• Swab (D): The lesion is unlikely to be infectious given the history and appearance. A biopsy is needed.
• Reassurance (E): This is unsafe and represents a significant missed opportunity for diagnosis.

This question addresses the management of recurrent vulvovaginal candidiasis (VVC) in pregnancy, which is a common and troublesome issue.

Conclusion:

Since this patient has had a rapid recurrence after a single-dose treatment, she has complicated/recurrent VVC. Simply repeating the single dose (Option C) is unlikely to be effective long-term. The most appropriate management is to use a longer, suppressive course of topical therapy to gain control of the infection, as described in Option B.

This question tests understanding of the pathophysiology of congenital syphilis.

The risk of mother-to-child transmission (MTCT) of syphilis is dependent on two main factors: the stage of maternal infection and the gestational age at which transmission occurs.

Therefore, the risk of transmission is lowest if treatment is given before 28 weeks, as the risk increases significantly after this point.

This question addresses the safety of medications for bacterial vaginosis (BV) during breastfeeding. The key principle is to choose an effective treatment that minimises infant exposure.

Why other options are incorrect:

• Doxycycline (D) and Ciprofloxacin (E): These are not standard treatments for BV. Doxycycline is also generally avoided in breastfeeding.

Advising the GP to prescribe topical metronidazole gel is the most appropriate and evidence-based recommendation.

The combination of symptoms following a recent miscarriage is highly suggestive of a complication that requires urgent evaluation.

Why Urgent Assessment is Essential:

It is not safe to manage this situation over the phone. The patient needs a face-to-face clinical assessment, which should include:

• Vital signs: To check for signs of sepsis (fever, tachycardia, hypotension).
• Abdominal and pelvic examination: To assess for uterine tenderness, cervical motion tenderness, and the nature of the discharge.
• Investigations: A transvaginal ultrasound scan to look for RPOC, and swabs for microbiology.

Why other options are incorrect:

• Options B and D (Reassurance/GP): This is unsafe as it trivialises potentially serious symptoms and delays diagnosis and treatment.
• Option C (Antibiotics over the phone): “Blind” prescribing without an examination is poor practice and could miss a surgical issue like an abscess or significant RPOC requiring evacuation.
• Option E (Routine scan): The assessment needs to be urgent, not routine, due to the risk of sepsis.

This question tests the understanding of the follow-up required after conservative surgical management of an ectopic pregnancy.

Therefore, the primary reason for post-operative hCG monitoring after salpingostomy is specifically to detect persistent trophoblast.

This question tests fundamental knowledge of the genetics of Gestational Trophoblastic Disease (GTD).

A partial mole is characterised by being triploid, containing one set of maternal chromosomes and two sets of paternal chromosomes. This results from the fertilisation of a normal haploid ovum by two separate sperm (dispermy), which is the most common mechanism. If one sperm carries an X chromosome and the other carries a Y chromosome, the resulting karyotype will be 69,XXY. This is the most frequently observed karyotype in partial moles.

This question balances the need for appropriate investigation of persistent symptoms against the concerns of radiation exposure in pregnancy.

The Principle: Maternal health is paramount. Investigations that are clinically indicated should not be withheld due to pregnancy, but steps should be taken to minimise fetal exposure to ionising radiation.

Clinical Rationale:

A persistent cough for two months warrants investigation to rule out underlying pathology such as pneumonia, tuberculosis, or, rarely, malignancy. A chest X-ray is the appropriate first-line imaging modality. Using an abdominal lead shield further minimises the already tiny fetal dose.

• Option C (PFTs): Useful for assessing conditions like asthma, but would not identify consolidation or a mass.
• Option D (Reassurance): Inappropriate given the duration of symptoms without a diagnosis.
• Option E (Sputum for TB): A reasonable test, but imaging is also required to look for signs of active pulmonary TB.

This question addresses the most effective methods for training in obstetric emergencies. The evidence, popularised by training programs like PROMPT (PRactical Obstetric Multi-Professional Training), strongly supports a specific type of simulation training.

Studies have shown that implementing regular, local, multidisciplinary training has led to significant improvements in outcomes for emergencies like shoulder dystocia and eclampsia, including a reduction in neonatal injuries.

Why other options are less effective:

• E-learning (A) and lectures (D): These are useful for knowledge acquisition but are poor at teaching practical skills and teamwork.
• Individual training (B): Fails to address the crucial team-based nature of emergency management.

While alcohol is the most common cause of acute pancreatitis in the general population, the epidemiology is different in pregnancy.

Why other options are less common in pregnancy:

• Alcohol (B): While a major cause overall, it is a less frequent cause during pregnancy due to reduced consumption.
• Hypertriglyceridemia (C): A recognised cause, as pregnancy itself is a state of hyperlipidemia. However, it is less common than gallstones unless there is a pre-existing familial hyperlipidemia.
• Idiopathic (D): A significant proportion of cases have no identifiable cause, but gallstones remain the most common identified cause.

Management: The initial management is supportive (IV fluids, analgesia, bowel rest). The definitive investigation to confirm the cause is an abdominal ultrasound to look for gallstones. An MRCP may be required if the ultrasound is inconclusive.

This question tests the precise application of the Advanced Life Support (ALS) algorithm for non-shockable rhythms (PEA and Asystole).

In this scenario:

• The first dose of adrenaline was given at the start of the last 2-minute cycle.
• The rhythm check after that cycle shows persistent PEA.
• According to the algorithm, the next step is to immediately resume CPR for another 2-minute cycle.
• The next dose of adrenaline is due after this next cycle is complete.

Therefore, continuing CPR for 2 minutes (Option D) is the correct next step before considering the second drug dose. Giving adrenaline again immediately (Option A) would be too soon.

• Shocks (B) and Amiodarone (E) are only used for shockable rhythms (VF/pulseless VT).
• A pulse check (C) is only performed if an organised rhythm compatible with a pulse is seen on the monitor.

The clinical picture is suggestive of iatrogenic hyponatremia caused by the oxytocin infusion.

Management Priorities:

1. Stop the Cause: The most important first step is to remove the offending agent. The oxytocin infusion must be stopped immediately to remove the antidiuretic stimulus.
2. Fluid Restriction: The second step is to strictly restrict fluid intake (both oral and IV) to allow the kidneys to excrete the excess free water and for the sodium level to correct itself. A rate of 80 ml/hour (Option A) is a reasonable restriction.

While fluid restriction is a key part of the management, stopping the oxytocin is the most critical initial action to halt the underlying pathological process. Administering more fluid (Options C and E) would worsen the dilutional hyponatremia. Hypertonic saline (Option D) is reserved for severe, symptomatic hyponatremia and requires specialist input and intensive monitoring.

This scenario describes a major intraoperative complication: significant, uncontrolled haemorrhage. The management of such an event follows clear surgical principles.

Why other options are incorrect:

• Calling a senior (A): This must be done, but it should not delay the decision to convert if bleeding is catastrophic. The immediate action is to prepare for conversion while calling for help.
• Abandoning the procedure (B): This is extremely dangerous. Closing the abdomen with an uncontrolled internal bleed would be fatal.
• Applying a haemostatic agent (D): These agents are for low-pressure venous oozing, not for an active arterial bleed from a major vessel.
• Continuing as consented (E): The primary goal has now shifted from the diagnostic procedure to life-saving haemorrhage control. Continuing with the original plan is inappropriate.

This question tests the understanding of what constitutes a good clinical audit. A clinical audit is a quality improvement process that seeks to improve patient care and outcomes by systematically reviewing care against explicit criteria and implementing change.

Analysis of the Options:

• Option B (Time to result): This is an excellent audit topic. The NHS Cervical Screening Programme sets clear standards for timeliness (e.g., 98% of women should receive their biopsy result within 8 weeks). You can measure your clinic’s performance against this standard, identify reasons for delays (e.g., lab turnaround, admin processes), implement changes, and re-audit.
• Options A, C, D, E: These are all examples of data collection or research, not audit. They describe a population (prevalence of HPV, average BMI, smoking status) but do not measure performance against a pre-defined standard of care. While the data might be interesting, it doesn’t fit the audit cycle. For example, there is no “standard” for what the average BMI of attendees should be.

The safety of vaccinations in pregnancy depends on whether the vaccine is live or inactivated.

The Yellow Fever Dilemma:

The Yellow Fever vaccine is a live attenuated vaccine and is therefore contraindicated. However, yellow fever disease itself has a high mortality rate. If travel to a high-risk, endemic area is unavoidable, the vaccine may be offered after careful counselling, as the risk from the disease is considered greater than the theoretical risk from the vaccine.

This question tests knowledge of drug interactions between antiepileptic drugs (AEDs) and hormonal contraception, guided by the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC).

The key interaction here is between lamotrigine and oestrogen.

Since the patient has declined an implant or intrauterine method, the desogestrel POP is a highly suitable and safe choice.

This patient is presenting with severe pre-eclampsia with clear signs of neurological involvement (headache, clonus), indicating she is at high risk of an imminent eclamptic seizure.

The management priorities, according to NICE guideline NG133, are:

1. Prevent seizures
2. Control severe hypertension
3. Plan for delivery

Management of other aspects:

• Blood Pressure Control (B, D): This is also vital. IV labetalol or hydralazine, or oral nifedipine, should be given concurrently to lower the BP and reduce the risk of stroke. However, preventing the seizure with MgSO4 is the immediate priority.
• Delivery (C): Delivery is the definitive cure for pre-eclampsia. However, the mother must be stabilised first. It is dangerous to proceed to anaesthesia and surgery in a woman on the verge of a seizure with uncontrolled hypertension. The MgSO4 and antihypertensives must be started first.

Therefore, administering the MgSO4 loading dose is the most critical initial action to stabilise the patient and prevent an eclamptic convulsion.

This question addresses the management of a pregnancy complicated by the presence of anti-Ro (SSA) and/or anti-La (SSB) antibodies.

This is a core knowledge question about the performance of the UK’s national screening test for aneuploidy.

Option B (DR 92% and FPR 2.5%) is the most accurate representation of the combined test’s performance. The other options describe the performance of different tests (e.g., the quadruple test has a lower DR of ~80%) or are inaccurate.

The type of ovarian malignancy is strongly correlated with age. In young women (<30 years old), malignant germ cell tumours are the most common type of ovarian cancer, whereas epithelial tumours are more common in older, post-menopausal women.

Therefore, when a young woman presents with a suspicious ovarian mass, the panel of tumour markers must be tailored to screen for germ cell tumours.

For a 22-year-old, the standard panel to request is AFP, LDH, and hCG to cover the main types of malignant germ cell tumours. While a CA-125 is often also checked, the germ cell markers are the most critical in this age group.

• Option C (CA-125 only) would be insufficient and could miss a germ cell tumour.
• Option E (CEA, CA 19-9) are markers for gastrointestinal cancers and would be checked if a Krukenberg tumour (metastasis to the ovary) was suspected.

The management of suspected DVT in pregnancy follows a specific pathway, but the definitive diagnostic imaging is well-established.

Why other options are incorrect:

• D-dimer (B): A D-dimer test is not useful for ruling out DVT in pregnancy. Pregnancy is a pro-inflammatory state, and D-dimer levels rise physiologically, leading to a high rate of false-positive results.
• CT venogram (C) and Contrast venography (E): Both involve significant radiation exposure and are not first-line tests in pregnancy.

The clinical presentation is that of a massive Pulmonary Embolism (PE), a life-threatening emergency. The patient is haemodynamically unstable (hypoxic) and has classic ECG and CXR signs of right heart strain.

Why other options are incorrect:

• V/Q scan (B): Inappropriate because the chest X-ray is abnormal.
• D-dimer (D): Not useful in pregnancy and completely irrelevant in a patient who has collapsed and is already on treatment for a known DVT.
• Pulmonary angiography (E): This is the historical gold standard but is an invasive procedure with higher risks and has been largely replaced by CTPA.

This question addresses the safety and risks of using ionising radiation for imaging during pregnancy.

Therefore, the primary fetal risk that needs to be discussed during counselling is the small, but real, increased lifetime risk of childhood cancer.

This question tests the specific follow-up protocol for partial hydatidiform moles, which differs from that for complete moles. This is guided by the RCOG Green-top Guideline No. 38 on Gestational Trophoblastic Disease.

The purpose of follow-up is to detect persistent trophoblastic disease, which is a pre-malignant condition that requires chemotherapy.

Applying to the question:

For a partial mole, the risk of persistent disease is very low. Therefore, the follow-up is less intensive than for a complete mole. The protocol is:

1. Measure serum hCG every 2 weeks until the level is normal (<5 IU/L).
2. Once a normal level is achieved, a final, confirmatory normal sample is taken 4 weeks later.
3. If this second sample is also normal, the patient can be discharged from follow-up.

This corresponds exactly to “two consecutive normal hCG levels measured 4 weeks apart” (the first normal level, and the second one 4 weeks later).

• Option C (6 months of normal levels) is the correct follow-up for a complete mole.

The management of a pregnant trauma patient follows the same ATLS (Advanced Trauma Life Support) principles as for a non-pregnant patient, with some key modifications. The overriding principle is that maternal life takes priority.

Imaging in Major Trauma:

• In a patient with high-energy trauma and haemodynamic instability, there is a high risk of multiple, life-threatening internal injuries.
• A CT pan-scan (typically including head, cervical spine, chest, abdomen, and pelvis) is the standard of care in major trauma centres to rapidly identify these injuries.
• While this involves a significant dose of ionising radiation, the risk of missing a fatal maternal injury (e.g., aortic dissection, solid organ laceration, pelvic fracture with haemorrhage) far outweighs the potential stochastic risk of radiation to the fetus.
• Limiting imaging to plain X-rays (Option B) is insufficient and could miss critical injuries.
• An MRI (Option C) is too slow and impractical in an unstable trauma patient.
• Delaying imaging (Option D) is not an option when the mother’s life is at risk.
• A FAST scan (Option E) is a useful adjunct in the primary survey to detect free fluid (blood) but it cannot identify many other life-threatening injuries and does not replace the need for a CT scan in major trauma.

In this scenario, adequate assessment of the adnexa is necessary as part of the investigation for post-menopausal bleeding, to rule out an ovarian cause.

Limitations of Ultrasound:

• Transvaginal ultrasound (TVS) is the first-line investigation for pelvic pathology.
• However, visualisation can be difficult in some women, particularly those with a high BMI, extensive adhesions, or post-menopausally when the ovaries are small and atrophic.
• If the ovaries are not seen on TVS, a transabdominal scan (Option D) is usually attempted as part of the same examination, but this is also often limited by body habitus.

Why other options are less appropriate:

• CT scan (B): While it can identify large masses, CT has poorer soft tissue resolution for gynaecological structures compared to MRI and involves ionising radiation. It is not the preferred second-line test for this indication.
• Repeat TVS (C): While sometimes helpful, if a competent sonographer has already failed to visualise the ovaries, a repeat scan is unlikely to yield a different result. Moving to a different imaging modality is more logical.
• No further imaging (E): This is incorrect. While a thin endometrium is reassuring regarding an endometrial cause for the bleeding, it does not exclude an adnexal pathology (e.g., a hormone-secreting ovarian tumour), which must be investigated.

To calculate the negative predictive value (NPV), we first need to construct a 2×2 contingency table from the data provided.

Step 1: Deconstruct the data

• Total population = 125
• Total with FGR (Disease Positive) = 25
• Total without FGR (Disease Negative) = 125 – 25 = 100
• Test positive in women with FGR (True Positives, TP) = 20
• Test positive in women without FGR (False Positives, FP) = 10

Step 2: Calculate the remaining values for the 2×2 table

• False Negatives (FN): Women with FGR who tested negative. FN = (Total with FGR) – (True Positives) = 25 – 20 = 5
• True Negatives (TN): Women without FGR who tested negative. TN = (Total without FGR) – (False Positives) = 100 – 10 = 90

Step 3: Construct the 2×2 table

Step 4: Calculate the Negative Predictive Value (NPV)

NPV is the probability that a person with a negative test result truly does not have the disease.

Formula: NPV = TN / (TN + FN)

• NPV = 90 / (90 + 5)
• NPV = 90 / 95
• NPV = 0.947

Converting to a percentage: 0.947 x 100 = 94.7%, which is approximately 95%.

This question requires selecting the correct statistical test based on the type of data and the study design.

Let’s break down the key information:

• Aim of the study: To compare the means of two independent groups.
• Data type: The outcome variable (pain score) is continuous/numerical.
• Number of groups: There are two groups (mesh technique 1 vs. mesh technique 2).
• Data distribution: The data is normally distributed.

This question asks for the definitive management of a large, symptomatic cervical fibroid in a woman who has completed her family.

Why other options are less appropriate:

• UAE (A): While an option for uterine fibroids, its efficacy for large, solitary cervical fibroids can be lower, and there is a risk of fibroid expulsion and other complications. It is not considered the definitive surgical treatment.
• Cervical myomectomy (C): This is a fertility-sparing procedure. It is technically very challenging for a large (8 cm) cervical fibroid due to the distorted anatomy and proximity to the ureters and major vessels, with a high risk of haemorrhage and ureteric injury. It is not the first choice for a woman who has completed her family.
• Hysteroscopic resection (D): This is only suitable for submucosal fibroids (Type 0, 1, 2) that are located within the uterine cavity, not for a large intramural cervical fibroid.
• Long-term GnRH agonist (E): This is not a long-term solution. It is used pre-operatively to shrink fibroids or as a temporary measure. Symptoms return once treatment stops, as experienced by the patient.

This question tests the ability to interpret a confidence interval (CI), a fundamental skill in critical appraisal of research.

Applying to this case:

• The mean difference was +4 points.
• The 95% CI was -1 to +9.
• Because this range includes negative values (-1), a zero value (no effect), and positive values (+9), we cannot be 95% confident that the true effect is different from zero.
• The CI is telling us that the true effect could plausibly be a small harm (a decrease of 1 point), no effect at all (zero), or a significant benefit (an increase of 9 points).
• Since we cannot rule out zero, the finding is not statistically significant.

Therefore, despite the observed mean improvement of 4 points in the sample, the study has failed to demonstrate a statistically significant effect of the treatment.

This patient is presenting with Diabetic Ketoacidosis (DKA), a life-threatening medical emergency for both mother and fetus. The presence of pre-eclampsia (hypertension and proteinuria) adds to the complexity and risk.

Why other options are incorrect:

• Betamethasone (B): Steroids cause hyperglycaemia and would significantly worsen the DKA. They should only be considered for fetal lung maturation after the DKA is fully resolved and under specialist guidance.
• Reassurance (D): Grossly inappropriate and dangerous.
• 5% Dextrose (E): This would be added to the fluid regimen later, once the blood glucose falls below a certain level (e.g., 14 mmol/L), to prevent hypoglycaemia while the insulin infusion continues to suppress ketones. It is not the initial fluid of choice.

This scenario involves a significant patient safety incident and requires an approach that combines honesty with the patient and adherence to clinical governance procedures.